Peptide Comparison

LixisenatidevsLiraglutide

Short-acting prandial GLP-1 receptor agonist for postprandial glucose control

FDA-approved once-daily GLP-1 receptor agonist (Victoza/Saxenda) that reduces HbA1c by 0.9–1.6%, promotes 5–10% body weight loss, and demonstrated a 13% reduction in major adverse cardiovascular events in the landmark LEADER trial of 9,340 patients

Weight ManagementWeight Management

At a Glance

Quick
comparison

Dose Range

Lixisenatide

10 mcg–20 mcg mcg

Liraglutide

0.6–3.0 mg

Frequency

Lixisenatide

Once daily

Liraglutide

Once daily

Administration

Lixisenatide

subcutaneous injection

Liraglutide

Subcutaneous injection

Cycle Length

Lixisenatide

Ongoing/indefinite

Liraglutide

Ongoing/indefinite

Onset Speed

Lixisenatide

Moderate (1-2 weeks)

Liraglutide

Gradual (3-4 weeks)

Evidence Level

Lixisenatide

Strong human trials (Phase 3 or FDA approved)

Liraglutide

Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefit
ratings

Lixisenatide

Liraglutide

Blood Sugar Control

Lixisenatide9%

Liraglutide0%

Cardiovascular Safety

Lixisenatide7%

Liraglutide0%

Weight Management

Lixisenatide6%

Liraglutide9%

Metabolic

Lixisenatide0%

Liraglutide9%

Healing & Recovery

Lixisenatide0%

Liraglutide8%

Technical Data

Compound
specifications

Lixisenatide

Molecular Formula

C₂₁₅H₃₄₇N₆₁O₆₅S

Molecular Weight

4,858 Da

Half-Life

2.8-3 hours

Bioavailability

55% subcutaneous bioavailability

CAS Number

320367-13-3

Liraglutide

Molecular Formula

C₁₇₂H₂₆₅N₄₃O₅₁

Molecular Weight

3,751 Da

Half-Life

~13 hours (enabling once-daily dosing); Tmax 8–12 hours; steady state in 3–5 days

Bioavailability

~55% after subcutaneous injection; >98% plasma protein binding to albumin via C16 fatty acid moiety

CAS Number

204656-20-2

Protocols

Dosing
tiers

Lixisenatide

Liraglutide

starting

0.6 mg subcutaneous once daily

Once daily

1 week (tolerability assessment)

Begin at 0.6 mg daily for the first week to assess gastrointestinal tolerability before dose escalation. This starting dose is sub-therapeutic for both diabetes and obesity indications. Inject in abdomen, thigh, or upper arm at any time of day regardless of meals. Rotate injection sites. GI side effects (nausea) are most common during the initial titration period.

standard

1.2–1.8 mg subcutaneous once daily

Once daily

Ongoing chronic therapy

Standard therapeutic dose range for type 2 diabetes (Victoza). Escalate from 0.6 mg to 1.2 mg at week 2 and optionally to 1.8 mg at week 3 for additional glycemic benefit. Maximum diabetes dose is 1.8 mg/day. No dose adjustment needed for renal or hepatic impairment. If combining with sulfonylureas, reduce sulfonylurea dose by 50% to minimize hypoglycemia. Store in-use pen at room temperature or refrigerated for up to 30 days.

advanced

3.0 mg subcutaneous once daily

Once daily

Ongoing chronic therapy with 16-week efficacy assessment

Obesity dose (Saxenda) reached through weekly 0.6 mg increments: 0.6→1.2→1.8→2.4→3.0 mg over 5 weeks. Evaluate response at 16 weeks — if <4% body weight loss, consider discontinuation as unlikely to achieve meaningful benefit. Must be combined with reduced-calorie diet and increased physical activity. Approved for BMI ≥30 or BMI ≥27 with weight-related comorbidities. Do not use simultaneously with Victoza or any other GLP-1 RA.

Applications

Best
suited for

Lixisenatide

Managing postprandial hyperglycemia in type 2 diabetes

Lixisenatide is particularly well-suited for individuals focused on managing postprandial hyperglycemia in type 2 diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Improving glycemic control as add-on to oral antidiabetics

Lixisenatide is particularly well-suited for individuals focused on improving glycemic control as add-on to oral antidiabetics. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Supporting weight management in T2DM patients

Lixisenatide is particularly well-suited for individuals focused on supporting weight management in t2dm patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Combination therapy with basal insulin glargine

Lixisenatide is particularly well-suited for individuals focused on combination therapy with basal insulin glargine. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Liraglutide

Type 2 diabetes patients with HbA1c >7% requiring both glycemic control and weight management

Liraglutide is particularly well-suited for individuals focused on type 2 diabetes patients with hba1c >7% requiring both glycemic control and weight management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Obese individuals (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities seeking FDA-approved pharmacotherapy

Liraglutide is particularly well-suited for individuals focused on obese individuals (bmi ≥30) or overweight (bmi ≥27) with weight-related comorbidities seeking fda-approved pharmacotherapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy

Liraglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile

Liraglutide is particularly well-suited for individuals focused on patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Side
effects

Lixisenatide

Common

Nausea
Vomiting
Diarrhea
Headache

Uncommon

Injection Site Reactions

Serious

Acute Pancreatitis

Liraglutide

Common

Nausea
Diarrhea
Vomiting
Decreased appetite and headache

Uncommon

Injection site reactions

Serious

Acute pancreatitis
Gallbladder disease

Research Status

Safety
& evidence

Lixisenatide

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Lixisenatide (Lyxumia, Adlyxin) is an FDA and EMA-approved GLP-1 receptor agonist with safety data from Phase 3 trials (LEAD program, 2012-2013) involving 4,000+ patients with type 2 diabetes. Gastrointestinal side effects (nausea, vomiting) are most common during dose escalation (30-40% of patients) but typically resolve after 2-3 weeks of stable dosing. The short half-life (3 hours) compared to longer-acting GLP-1 agonists means side effects have rapid onset and offset. No serious adverse events exceed background diabetes population rates in pivotal trials.

Contraindications

xKnown hypersensitivity to lixisenatide or excipients
xPersonal or family history of medullary thyroid carcinoma
xPatients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
xSevere gastrointestinal disease including gastroparesis

Liraglutide

Evidence Level

Strong human trials (Phase 3 or FDA approved)

FDA Status

FDA approved for this use

Safety Overview

Liraglutide (Victoza, Saxenda) is FDA-approved with extensive safety data from 15+ years of clinical use in diabetes (GLP-1 agonist) and obesity indications. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of patients during dose escalation but diminish significantly after 2-3 weeks of stable dosing. Black box warnings include risk of medullary thyroid carcinoma and pancreatitis, though absolute incidence remains rare. Injection site reactions are minimal. The compound shows no hepatotoxicity, nephrotoxicity, or major drug interactions at approved doses.

Contraindications

xPersonal or family history of medullary thyroid carcinoma (MTC) — black box warning based on rodent thyroid C-cell tumor findings
xMultiple Endocrine Neoplasia syndrome type 2 (MEN 2)
xKnown hypersensitivity to liraglutide or any excipients
xPregnancy (Saxenda indication) — contraindicated; effective contraception required

Decision Guide

Which is
right for you?

Choose Lixisenatide if...

Managing postprandial hyperglycemia in type 2 diabetes
Improving glycemic control as add-on to oral antidiabetics
Supporting weight management in T2DM patients
Combination therapy with basal insulin glargine

Choose Liraglutide if...

Type 2 diabetes patients with HbA1c >7% requiring both glycemic control and weight management
Obese individuals (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities seeking FDA-approved pharmacotherapy
Patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy
Patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile

Full Lixisenatide Profile Full Liraglutide Profile

Peptide Database

Quickcomparison

Benefitratings

Compoundspecifications

Dosingtiers

Bestsuited for

Sideeffects

Safety& evidence

Which isright for you?

Quick
comparison

Benefit
ratings

Compound
specifications

Dosing
tiers

Best
suited for

Side
effects

Safety
& evidence

Which is
right for you?